Medlab expects to roll this trial out to 2,000 patients across Australia, making it one of the most significant cannabis trials to date.
Showing 25 of 230
MMJ is a global cannabis investment company with a portfolio of listed and unlisted holdings.
The company’s medicinal cannabis products are aimed at treating pain, anxiety, sleep apnea and cancer.
The buy-back is from existing cash reserves and is expected to enhance shareholder returns.
The company has accumulated a pool of around 16,000 investors and shareholders funds of about A$90 million.
The agreement is with a major international Thai pharmaceutical company.
MMJ is the only ASX-listed investment company offering Australian investors the opportunity to invest in unlisted and listed cannabis-related businesses locally and offshore.
The company has a focus on clinical validation and is well placed to service a rapidly growing market.
Aiming to capitalise on the pending legalisation by the Canadian Federal Government of concentrates and vaporisers in October 2019.
Cash-strong MMJ’s market capitalisation is now about 57% of its net asset value.
The company’s research results into cannabinoid treatments for animals have been presented at a leading veterinary conference.
PCI Pharma has manufactured the first engineering batch of AusCann’s medical cannabis hard shell capsules for treatment of chronic pain, bringing the company closer to the release of its medicinal cannabis product line for clinical trials later this year.
The company will present findings of study into cannabinoid treatment for companion animals at AVA Innovation Symposium next month.
Medlab has two cannabis-based medicines, NanaBis™ and NanaBidial™.
The company is pleased with data it has collected to date for NanaBis.
The purchase follows the recent appointment to CEO of ex Teva Pharmaceutical executive, Ido Kanyon.
Ilera is a vertically integrated medicinal cannabis company with operations based in Pennsylvania and Louisiana.
Building an intellectual property portfolio is part of Zelda's vertically integrated strategy.
This program gives Asterion Australia the opportunity to supply its planned facility in South East Queensland with disease-free plantlets and genetically standardized marijuana strains
The development and distribution deal is in the form of a heads of agreement.
This is a niche space that is growing fast and CannPal already has an advantage through its research and product development programs which are well underway.
The study identifies a novel role for the CB2 cannabinoid receptor in HER2+ breast cancer, putting the company at the forefront of efforts to develop new cannabis treatments.
Ido Kanyon will replace interim CEO Dr Paul MacLeman on 22 May 2019.
The company’s cash at bank was $4.41 million at the end of the 2018 calendar year.
AC8 has all the necessary licenses to grow and manufacture cannabinoid medicines in Australia.